Analysis: 3B Blackbio DX Ltd

BSE:3BBLACKBIO Diagnostics Market cap: ₹1.3K cr

Why is 3B Blackbio DX Ltd stock rising?

  • us fda submission process for selected amr products, with successful clearance expected to provide access to significantly large us diagnostic market
  • targeting 15% to 20% revenue growth in '26-'27 through global expansion, including strengthening distributor partnerships and entering new geographies across europe, africa, asia pacific, middle east, and latin america
  • ivdr transition completed with bsi as notified body, positioning as competitive advantage in european markets
  • sample-to-answer system validation progressing, expected to launch in q3/q4 2026 with installations in 2-3 labs by end of 2026
  • coris bioconcept expected to grow to inr50-52 crores revenue in fy27, with ebitda margin improving to 5% to 7% in next 1-2 years

Research report

companyname: 3B BlackBio Dx Limited ticker: 3BBLACKBIO sector: Biotechnology / Molecular Diagnostics 3B BlackBio Dx Limited is an Indian biotechnology company that designs, manufactures, and sells molecular diagnostic kits - the reagents and test panels that laboratories use to detect infectious diseases, cancer markers, and antimicrobial resistance in patient samples. The company started its molecular diagnostics business around 2015, building on a corporate shell (Kilpest India Limited) that ...

Read the full report →

Growth guidance

FY27 revenue growth guided at 15-20% driven by expanding global presence through distributor partnerships and entering new geographies

Guidance upgraded
RS rating: 86 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for 3B Blackbio DX Ltd and 4,900+ companies.

Sign in
5-day free pass. No card required.
More in Diagnostics